Table 1 Clinical and pathological variables in ClinicoMolecular Triad Classification of breast cancer in training and validation cohorts

Total

45 (30.2)

65 (43.6)

39 (26.2)

803 (32.3)

794 (31.9)

890 (35.8)

Age

   < 50

15 (33.3)

18 (27.7)

17 (43.6)

2.51E-01

231 (39.1)

202 (34.9)

299 (43.6)

6.30E-03

   ≥ 50

30 (66.7)

47 (72.3)

22 (56.4)

360 (60.9)

377 (65.1)

386 (56.4)

Size

   ≤ 2 cm

23 (51.1)

21 (32.3)

11 (28.2)

5.62E-02

361 (54.7)

209 (32.5)

235 (32.4)

1.05E-20

   > 2 cm

22 (48.9)

44 (67.7)

28 (71.8)

299 (45.3)

434 (67.5)

490 (67.6)

LN-

26 (59.1)

21 (32.3)

24 (61.5)

3.27E-03

490 (66.8)

436 (59.2)

498 (60.3)

4.37E-03

LN+

18 (40.9)

44 (67.7)

15 (38.5)

243 (33.2)

301 (40.8)

328 (39.7)

Grade

   1

13 (28.9)

1 (1.5)

0 (0.0)

5.55E-13

270 (39.4)

81 (12.2)

29 (3.9)

3.47E-130

   2

27 (60.0)

30 (46.2)

6 (15.4)

342 (49.9)

339 (51.2)

220 (29.6)

   3

5 (11.1)

34 (52.3)

33 (84.6)

74 (10.8)

242 (36.6)

495 (66.5)

ER-

0 (0.0)

1 (1.5)

35 (89.7)

1.16E-27

69 (8.6)

45 (5.7)

584 (65.6)

2.60E-211

ER+

45 (100)

64 (98.5)

4 (10.3)

734 (91.4)

749 (94.3)

306 (34.4)

Her2+/TN

   No

42 (93.3)

60 (92.3)

3 (7.7)

1.87E-22

715 (89.0)

668 (84.1)

238 (26.7)

1.45E-197

   Yes

3 (6.7)

5 (7.7)

36 (92.3)

88 (11.0)

126 (15.9)

652 (73.3)

Recurrence

   No

44 (97.8)

61 (93.8)

34 (87.2)

1.49E-01

595 (81.4)

423 (59.5)

486 (61.0)

1.99E-22

   Yes

1 (2.2)

4 (6.2)

5 (12.8)

136 (18.6)

288 (40.5)

311 (39.0)